Research ArticleAccepted Articles
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna Gladman, Shamiza Hussein, Drew Neish and Patrick Leclerc
The Journal of Rheumatology January 2023, jrheum.220824; DOI: https://doi.org/10.3899/jrheum.220824
Robert D. Inman
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
Denis Choquette
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
Majed Khraishi
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
Dafna Gladman
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
Shamiza Hussein
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
Drew Neish
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
Patrick Leclerc
Funding: This study was sponsored by Novartis Pharmaceuticals Canada Inc. Author affiliations: R. D. Inman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. D. Choquette, MD, Institut de recherche en rhumatologie de Montréal, CHUM, Montréal, QC, Canada. M. Khraishi, MD, Nexus Clinical Research, Memorial University of Newfoundland, St. John's, NL, Canada. D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada. S. Hussein, MSc, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. D. Neish, MSc, IQVIA Canada, Kirkland, QC, Canada. P. Leclerc, PhD, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada. Conflict of interest: Dr. Robert Inman has received consulting fees from Abbvie, Janssen, Lilly, Novartis, and Sandoz. Dr. Denis Choquette has received research grant support from Abbvie, Amgen, Eli Lilly, Fresenius-Kabi, Novartis, Pfizer, Sandoz, Celltrion, Teva Pharmaceuticals, and Sanofi-Genzyme, and consulting or speaker fees from Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Celltrion, and Teva Pharmaceuticals. Dr. Majed Khraishi has received consulting fees from Abbvie, Amgen, Gilead, Novartis, Pfizer and UCB. Dr. Dafna Gladman has received research grant support from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and consulting fees from Abbvie, Amgen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. Patrick Leclerc and Shamiza Hussein are employees of Novartis Pharmaceuticals Canada Inc. Drew Neish is an employee of IQVIA. IQVIA received consulting fees from the sponsor, Novartis Pharmaceuticals Canada Inc., for the study. Corresponding Author: Dr. Robert Inman, Schroeder Arthritis Institute, 399 Bathurst St., Toronto, ON M5T 2S8, Canada robert.inman@uhn.ca
In this issue
The Journal of Rheumatology
Vol. 50, Issue 3
1 Mar 2023
Accepted manuscript
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc
The Journal of Rheumatology Jan 2023, jrheum.220824; DOI: 10.3899/jrheum.220824
Accepted manuscript
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc
The Journal of Rheumatology Jan 2023, jrheum.220824; DOI: 10.3899/jrheum.220824
